You are seeing this message because your Web browser does not support basic Web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.


ABOUT ARCHIVES
Advanced Search

Welcome   | My Account | E-mail Alerts | Access Rights | Sign In


  Vol. 61 No. 9, September 2004 TABLE OF CONTENTS
  Archives
  •  Online Features
  Original Contribution
 This Article
 •Full text
 •PDF
 • Reply to article
 •Send to a friend
 • Save in My Folder
 •Save to citation manager
 •Permissions
 Citing Articles
 •Citation map
 •Citing articles on HighWire
 •Contact me when this article is cited
 Related Content
 •Similar articles in this journal
 Topic Collections
 •Multiple Sclerosis/ Demyelinating Disease
 •Neuro-ophthalmology
 •Immunologic Disorders
 •Alert me on articles by topic
 Social Bookmarking
  Add to CiteULike Add to Connotea Add to Del.icio.us Add to Digg Add to Reddit Add to Technorati Add to Twitter What's this?

Neurologic Impairment 10 Years After Optic Neuritis

Optic Neuritis Study Group*

Arch Neurol. 2004;61:1386-1389.

Background  Participants enrolled in the Optic Neuritis Treatment Trial have been observed for more than a decade to assess the relationship between optic neuritis and the development of clinically definite multiple sclerosis.

Objective  To assess neurologic disability 10 to 12 years after an initial episode of optic neuritis.

Design  Longitudinal follow-up of a clinical trial.

Setting  Fourteen Optic Neuritis Treatment Trial clinical centers performed standardized neurologic examinations, including an assessment of neurologic disability.

Participants  One hundred twenty-seven patients who had developed clinically definite multiple sclerosis.

Main Outcome Measures  Functional Systems Scale and Expanded Disability Status Scale.

Results  The disability of most patients was mild, with 65% of patients having an Expanded Disability Status Scale score lower than 3.0. The degree of disability appeared to be unrelated to whether the baseline magnetic resonance imaging scan was lesion-free or showed lesions (P = .51). Among patients with baseline lesions, the degree of disability was unrelated to the number of lesions that were present on the scan (P = .14). Two patients died owing to severe multiple sclerosis, one of whom had no lesions revealed on the baseline scan.

Conclusion  Most patients who develop clinically definite multiple sclerosis following an initial episode of optic neuritis will have a relatively benign course for at least 10 years.



*Authors: The Writing Committee served as author for the Optic Neuritis Study Group.



Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Early MRI in optic neuritis: The risk for disability
Swanton et al.
Neurology 2009;72:542-550.
ABSTRACT | FULL TEXT  

The Optic Neuritis Treatment Trial: A Definitive Answer and Profound Impact With Unexpected Results
Volpe
Arch Ophthalmol 2008;126:996-999.
FULL TEXT  

Disability and T2 MRI lesions: a 20-year follow-up of patients with relapse onset of multiple sclerosis
Fisniku et al.
Brain 2008;131:808-817.
ABSTRACT | FULL TEXT  

Baseline MRI predicts future attacks and disability in clinically isolated syndromes.
Tintore et al.
Neurology 2006;67:968-972.
ABSTRACT | FULL TEXT  

Axonal injury in early multiple sclerosis is irreversible and independent of the short-term disease evolution
Rovaris et al.
Neurology 2005;65:1626-1630.
ABSTRACT | FULL TEXT  

Optic Neuritis and Multiple Sclerosis: Long-term Prognostic Considerations
Kattah
Arch Neurol 2005;62:506-506.
FULL TEXT  

Disability Level Low 10 Years After Optic Neuritis
JWatch Neurology 2005;2005:5-5.
FULL TEXT  





HOME | CURRENT ISSUE | PAST ISSUES | TOPIC COLLECTIONS | CME | SUBMIT | SUBSCRIBE | HELP
CONDITIONS OF USE | PRIVACY POLICY | CONTACT US | SITE MAP
 
© 2004 American Medical Association. All Rights Reserved.